In this episode of Beatwise The Podcast, I’m joined by renowned cardiologist Dr. Muthu Vaduganathan to dive deep into one of the most exciting developments in cardiorenal medicine: Finerenone. We explore its role as a mineralocorticoid receptor antagonist and its game-changing potential in treating patients with chronic kidney disease (CKD) and type 2 diabetes - two conditions that often go hand-in-hand with heart failure.We break down key insights from landmark clinical trials, including the FINEARTS-HF trial, and how Finerenone is reshaping treatment strategies for both kidney and heart health. Dr. Vaduganathan also shares practical guidance on integrating Finerenone into clinical practice, potential side effects to consider, and why patient involvement in research is more important than ever. If you’re a clinician, researcher, or someone passionate about emerging treatments in cardiovascular care, this one’s for you.EPISODE HIGHLIGHTS:[0:00] - Welcome to Beatwise The Podcast[0:31] - Meet Dr. Muthu Vaduganathan: Leading voice in cardiovascular medicine[0:57] - What is Finerenone? Understanding this novel therapy[2:23] - How Finerenone compares to current treatment options[4:08] - Landmark kidney trials: Finerenone’s impact in CKD and T2D[7:26] - Clinical insights from the FINEARTS-HF trial and heart failure care[12:43] - Encouraging patient participation in trials and treatment decisions[17:14] - Where guidelines stand now - and where they’re headed next[21:34] - Final thoughts and key takeaways for clinicians and patients alikeIf you enjoyed this episode, please like, rate, and subscribe to Beatwise The Podcast. Your support helps me reach more listeners and continue providing valuable content.Don't forget to follow me on social media @sarah.theheartdoc for the latest updates, behind-the-scenes content, and more engaging discussions. Stay connected and be part of our growing community! Hosted on Acast. See acast.com/privacy for more information.

Ver todos los episodios